Total Funding
79
47
Total FundingPost-IPO Debt raised
Growth Score
-7 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
115535
CASI focus on building a pipeline through mutually beneficial business development transactions.
John W Holaday: co-founderPast Role: QRxPharma, CEO
About the Company
CASI Pharmaceuticals, Inc. ("CASI", "we" or "us") is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. CASI is focused on acquiring, developing and commercializing products that augment
its hematology oncology therapeutic focus as well as other areas of unmet medical need. CASI is executing its plan to become a biopharmaceutical leader by launching medicines in the greater China market leveraging CASI's China-based regulatory and commercial competencies and its global drug development expertise.
